Compumedics delivers record H1 FY26 sales orders; shipped revenue up 32%, positioning for stronger H2 and FY26 execution

Strong SaaS revenue growth and ongoing MEG sales momentum underpin H1 FY26 growth, driving earnings higher; Somfit D launch to come in H2 FY26.

BUSINESS Update

1. Sales Orders Taken

• Record sales orders taken of $34.9 million for H1 FY26, up 6% on H1 FY25 ($32.8 million)
• The record order intake reflects strengthening demand and improved conversion across Compumedics’ core sleep and neuro platforms, following a targeted USA commercial refocus.
• MEG: the Company secured one MEG order in H1 FY26, with further MEG opportunities expected to progress in H2 FY26.

2. Revenue Reported (unaudited)

• Record reported revenue (shipped and invoiced) of $30.8 million for H1 FY26, up 32% on H1 FY25 ($23.2 million)
• The result reflects improved execution and delivery cadence, converting order momentum into shipped and invoiced revenue, with MEG contributing to ongoing invoicing.
• Reported revenue will continue to reflect delivery and installation timing, particularly for capital equipment and MEG systems.

3. Cost Base and Profitability

• The Company is progressing a $2 million p.a. cost-out program to lift operating leverage and support margin expansion, while maintaining investment in priority growth initiatives
• The program is focused on structural efficiency, reduced overhead intensity and stronger capital discipline, with benefits expected to build through H2 FY26.
• Compumedics H1 FY26 EBITDA (subject to audit) is expected to exceed $3 million.

4. Outlook

• FY26 guidance reaffirmed:
  • Revenue: $70 million
  • EBITDA: up to $9 million
• The Company expects a stronger second half profile, underpinned by improving shipment conversion, the progressive impact of the cost-out program, and high-value product and pipeline catalysts.
• MEG: one order secured in H1 FY26, with additional MEG orders expected in H2 FY26. Existing MEG orders are on track for H2 FY26 shipment, with shipments for new orders now continuing into FY27.
• Somfit D: launch targeted for H2 FY26, providing a 2026 catalyst to accelerate penetration in the large home sleep testing market in the USA and expand contribution from connected, higher margin platforms over time.
• USA restructure: the Company has implemented a targeted USA commercial restructure to improve sales execution efficiency, increase focus on high-probability opportunities and accelerate customer onboarding and conversion, including in preparation for the Somfit D launch.
• Funding: the Company is progressing additional bank funding capacity to support growth and working capital requirements as scale increases, strengthening financial flexibility and enabling the Company to pursue larger opportunities with confidence.

 
Compumedics Limited (ASX: CMP), a global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain and ultrasonic blood flow monitoring, is pleased to provide this H1 FY26 business update.

 
Executive Chairman Dr. David Burton commented:
“Compumedics is demonstrating clear strategic and operational momentum, delivering record first half sales orders and shipped revenue growth, while progressing MEG opportunities and expanding our connected Somfit platform. Importantly, we are converting that momentum into scale, with improving delivery cadence and a sharpened cost base that supports operating leverage. With Somfit D planned for launch in the second half and a $20 million pipeline already identified, alongside MEG opportunities advancing and additional bank funding capacity being progressed, we believe the Company is well positioned to deliver on FY26 guidance and continue building a higher quality earnings profile with increasing recurring and connected platform contribution.”
 

 
The Appendix 4D is expected to be released with the H1 FY26 results on or around 23 February 2026.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company involved in the development, manufacture and commercialisation of diagnostics technology for the sleep, brain and ultrasonic blood-flow monitoring applications. The Company owns US based Neuroscan and Germany based DWL Elektronishe GmbH. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. In the same year the Company successfully designed and installed the first Australian, fully computerised sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on the development of products that sold into the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian governments.

For further information please contact:

Dr David Burton
Executive Chairman, CEO
Compumedics Limited
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

David Lawson
Director, CFO
Compumedics Limited
Phone: + 61 3 8420 7300
Fax: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited’s Board of Directors